- FDA approved Rasonque (daraxonrasib), a daily pill for the most common form of pancreatic cancer — patients in trials nearly doubled median survival (13.2 vs. 6.7 months) and had fewer severe side effects.
- It targets KRAS mutations long considered "undruggable" using a molecular‑glue approach, a breakthrough that could open doors for treatments in other cancers.
- The drug drew public attention after former Sen. Ben Sasse reported less pain while taking it; FDA had allowed expanded access and approved it more than six months early.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.